GGrantIndex
← Search

Research Program: Cancer Basic Biology

$95,890P30FY2020CANIH

Fred Hutchinson Cancer Research Center, Seattle WA

Investigators

Linked publications, trials & patents

Trial NCT06995898Trial NCT06682039Trial NCT06484595Trial NCT06193070Trial NCT05947500Trial NCT05930496Trial NCT05183828Trial NCT04902144Trial NCT04751383Trial NCT04682301Trial NCT04667481Trial NCT04660331Trial NCT04539366Trial NCT04505553Trial NCT04502524Trial NCT04500548Trial NCT04496219Trial NCT04489719Trial NCT04472338Trial NCT04466475Trial NCT04447313Trial NCT04444232Trial NCT04442581Trial NCT04431479Trial NCT04410900Trial NCT04387227Trial NCT04384692Trial NCT04383743Trial NCT04375631Trial NCT04372927Trial NCT04370301Trial NCT04359784Trial NCT04336943Trial NCT04329065Trial NCT04282187Trial NCT04260776Trial NCT04257578Trial NCT04254133Trial NCT04231877Trial NCT04220229Trial NCT04211766Trial NCT04208724Trial NCT04205409Trial NCT04200482Trial NCT04198922Trial NCT04196010Trial NCT04195945Trial NCT04195633Trial NCT04194918Trial NCT04188912Trial NCT04175431Trial NCT04156828Trial NCT04155840Trial NCT04151940Trial NCT04120246Trial NCT04111497Trial NCT04083183Trial NCT04083170Trial NCT04081779Trial NCT04081298Trial NCT04062955Trial NCT04060849Trial NCT03999515Trial NCT03991884Trial NCT03986502Trial NCT03980769Trial NCT03970096Trial NCT03907527Trial NCT03891784Trial NCT03864419Trial NCT03807063Trial NCT03806192Trial NCT03781778Trial NCT03779867Trial NCT03779854Trial NCT03778021Trial NCT03776864Trial NCT03749460Trial NCT03747484Trial NCT03737955Trial NCT03723863Trial NCT03718338Trial NCT03672981Trial NCT03670966Trial NCT03670069Trial NCT03660930Trial NCT03649841Trial NCT03641287Trial NCT03606486Trial NCT03602898Trial NCT03600038Trial NCT03585231Trial NCT03574012Trial NCT03570476Trial NCT03531918Trial NCT03525106Trial NCT03523195Trial NCT03522584Trial NCT03518242Trial NCT03516812

Abstract

PROJECT SUMMARY: CANCER BASIC BIOLOGY (CBB) Cancer Basic Biology (CBB) is the sole fundamental science program in the Cancer Consortium. Its mission is three-fold: to conduct basic biological research related to cancer; to enable and conduct translational research that brings basic research findings to preclinical and clinical studies; and to train and mentor the next generation of cancer researchers. Scientifically, CBB research has three Specific Aims: (1) to elucidate the fundamental mechanisms that drive normal and cancer cell biology; (2) to use advanced genomics and epigenomics technologies to understand gene expression and phenotype in normal and cancer cells; and (3) to develop and apply new tools to facilitate basic science and cancer cell analyses. Each of these aims has a basic (discovery) and a translational (preclinical) component. The CBB Program leadership represents all three academic institutions and the breadth of fundamental research on cancer. Program Co-Leaders Jonathan Cooper and Ray Monnat take responsibility for cell biology and genomics/epigenomics, respectively. Associate Program Leaders David MacPherson and Barry Gumbiner add strength in animal models and cell/structural biology. All four CBB leaders are united in the goals of fostering research on the basic biology of normal and cancer cells and in promoting the development and application of new tools to improve cancer diagnosis and therapy. The program benefits the catchment area through research on lung, brain, and other cancer types that cause significant mortality and morbidity in our area. Our program structure and leadership work to foster high quality, cutting edge science within CBB and across Research Programs by providing opportunities to meet, share ideas, and develop new collaborative opportunities. We actively recruit new members with cancer- specific expertise, and identify new ways to promote both collaborative and translational science. CBB members play an additional key role in training the next generation of cancer scientists. The CBB Program currently has 105 members with 38 based at Fred Hutch, 63 based at University of Washington, and 4 based at Seattle Children?s. Since the prior cycle, CBB has gained a net of 32 members. The current research support of CBB members is $43.2M (direct costs), of which $27.3M is peer-reviewed funding, including $9M from the NCI. CBB Program members published a total of 1,057 papers over the current grant period, of which 12% were intra-programmatic, 16% were inter-programmatic, and 48% had external co-authors. Eleven of the 12 Consortium Shared Resources were utilized by CBB members in the course of their work. This P30 grant assists this program by providing administrative and logistical support for CBB meetings, pilot funding for new research projects, and recruitment resources for new faculty.

View original record on NIH RePORTER →